Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), likely interfere with the study procedures or results
Patients with any clinical significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) that is likely to interfere with the study procedures or results
Concurrent Illness* Patients with active autoimmune disease or documented history of autoimmune disease/syndrome that requires ongoing systemic steroids or systemic immunosuppressive agents, except ** Patients with vitiligo or resolved asthma/atopy** Patients with hypothyroidism stable on hormone replacement or Sjogren�s syndrome * History of or ongoing pneumonitis or significant interstitial lung diseaseNote: This would include non-infectious pneumonitis that required steroid use* Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient�s ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results* Patients with other current malignancies* Patients with known hypermutated brain tumors including those with CMMRD and Lynch syndrome are ineligible for enrollment in Strata A, B, D and E* Patients who have received a solid organ transplant
EXCLUSION CRITERIA FOR STRATUM C: Concurrent illness* Patients with active autoimmune disease or documented history of autoimmune disease/syndrome that requires ongoing systemic steroids or systemic immunosuppressive agents, except ** Patients with vitiligo or resolved asthma/atopy** Patients with hypothyroidism stable on hormone replacement or Sjogren�s syndrome * History of or ongoing pneumonitis or significant interstitial lung disease* Note: This would include non-infectious pneumonitis that required steroid use* Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient�s ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results** Exception to this is the presence of gastrointestinal polyps/adenomas and non-metastatic carcinomas, and history of any previous malignancies in patients with CMMRD which will be allowed in this study* Patients who have received a solid organ transplant
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the ability of the patient to tolerate protocol therapy or put them at additional risk for toxicity or would interfere with the study procedures or results
NON-PROGRESSED DIPG (STRATUM 2): Patients have any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the ability of the patient to tolerate protocol therapy or put them at additional risk for toxicity or would interfere with the study procedures or results
Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient�s ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results